Prostate Squamous Cell Carcinoma
NCI Definition: An invasive prostate carcinoma characterized by the presence of squamous differentiation of the malignant cellular infiltrate. There is no evidence of glandular differentiation. 
Prostate squamous cell carcinomas most frequently harbor alterations in TP53, SPEN, REL, PIK3CA, and NFE2L2 .
TP53fs, SPEN V879G, REL P450S, PIK3CA Mutation, and PIK3CA E545K are the most common alterations in prostate squamous cell carcinoma .
There is 1 clinical trial for prostate squamous cell carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains prostate squamous cell carcinoma as an inclusion criterion, 1 is phase 2 (1 open).
Ipilimumab and nivolumab are the most common interventions in prostate squamous cell carcinoma clinical trials.
Significant Genes in Prostate Squamous Cell Carcinoma
CD274 is an inclusion eligibility criterion in 1 clinical trial for prostate squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and prostate squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.